Sigumir

Sigumir is one of the tissue-specific peptide bioregulators from the Khavinson program at the St Petersburg Institute of Bioregulation and Gerontology: an extract of cartilage and bone from young animals, sold in 30-day courses on the premise that peptides taken from a tissue regulate the aging of that same tissue. In the institute's own papers the substance appears under a different name — the cartilage polypeptide complex — and that is the name under which almost all of its laboratory record was published.

What is in the capsule

One published analysis exists. Mass spectrometry and HPLC put the complex's contents at short peptides ranging from 75 to 846 daltons, among them the tripeptide Ala-Glu-Asp that the same institute sells separately as Cartalax. The program's worked example of that method, applied to its pineal extract, broke the complex down to 3.26% free amino acids, 23.19% dipeptides, 50.72% tripeptides, 22.10% tetrapeptides and 0.72% pentapeptides.

That gives the product a plausible active-fraction story: the extract is a carrier for short peptides, and the short peptides are the thing. It is a single analysis, from the manufacturer's own institute, in a journal PubMed does not index, and no outside laboratory has repeated it or reported batch-to-batch variation. Composition is also not efficacy — knowing what is in a capsule and knowing what it does are separate questions.

The cartilage laboratory work

In 2023 the institute published the first cartilage-cell results for the complex. In human mesenchymal stem cells aged by repeated division, it raised gene expression and protein synthesis of SOX9, aggrecan, type II collagen and COMP at 2,000 ng/ml — and at 200 ng/ml it moved neither SOX9 nor aggrecan, so the effect belongs to the higher concentration. In rat chondrocytes grown out of intervertebral discs, carrying the senescence-associated secretory phenotype, it lowered p16, p21, p53, TNF-alpha and IL-1-alpha and raised Sirt1; it is the one of the two preparations that moved the cytokines, which the AED tripeptide did not. A sibling extract, Chondrolux, stimulated growth in organotypic cartilage cultures from both young and old rats at 20 to 50 ng/ml, with PCNA rising and p53 falling.

The animal work is about bone. In ovariectomised rats, a preparation based on cartilaginous tissue extract prevented the loss of bone mineral density when given before surgery and raised density that had already fallen when given after; cartilage and bone extracts placed into a cortical bone defect sped repair in old animals; Chondrolux applied to skin wounds in old rabbits brought granulation tissue forward from days 21–28 to day 14. Bone density and wound healing are respectable endpoints, and none of them is articular cartilage.

Running through all of it is one gap that decides the tier: no published paper says that the cartilage polypeptide complex studied in these experiments is the preparation sold as Sigumir. They are described the same way and come from the same institute. The identification is an inference, and this entry treats it as one.

The human evidence

One indexed human study names Sigumir, and it does have a control group: 62 elderly patients with temporomandibular arthrosis, arthrosis-arthritis or joint dysfunction, of whom 38 took Sigumir — a capsule twice daily for a month — on top of dental prosthetic work, functional therapy and pharmacotherapy, and 24 had those without it. So the peptide is the only difference between the groups. Pain resolved at 10.3 days against 12.7, and the joint's clicking and crunching at 17.1 days against 18.3, both on standard deviations that overlap and neither with a between-group test. On everything else measured, the paper reports no statistically significant difference from the control group. Allocation was not randomised and nobody was blinded. A second study in the same journal treated 104 men aged 35 to 74 with temporomandibular joint dysfunction and reported their severity index falling from 7, 9 and 13 points across three age bands to 4, 6 and 9 after a 60-day course, which is the shift from severe to moderate it claims for the oldest group. Nobody went untreated, and no test on the change is reported. The agent was Cartalax, not this one.

The program's flagship human result used thymic and pineal extracts rather than this one: 266 elderly people followed 6 to 8 years, with six-year mortality of 81.8% among 22 placebo controls against 41.7%, 45.8% and 33.3% in the three treated groups of 24 apiece. Those are the figures behind the 2.0 to 2.5 times the program quotes, and they are ratios of crude percentages. Its joint endpoint is a tally of how often a patient saw a doctor about deforming osteoarthrosis over four months before and four months after treatment, in people who already had it. The report describes stratification randomisation, a placebo control and double blinding; it gives no allocation concealment, no confidence intervals and no estimate beyond those ratios.

The one preparation of this kind that was trialled

Rumalon is the same idea in injectable form — an aqueous extract of bovine cartilage and bone marrow, given intramuscularly, used for osteoarthritis in Europe for decades. It got the trial Sigumir has never had: five years, double blind, placebo controlled, 394 patients with knee or hip osteoarthritis, ten courses of fifteen injections, with radiographic joint space as the primary endpoint.

Knee joint space narrowed 0.37 ± 0.08 mm on the extract against 0.42 ± 0.08 mm on placebo, P = 0.68. Hip narrowed 0.21 ± 0.08 against 0.22 ± 0.08 mm, P = 0.53. The Lequesne algofunctional index, pain on passive motion and NSAID consumption did not separate either. Side effects ran 14.5% against 15% on placebo. A 2021 Russian observational study of 2,955 patients on the same injections reported pain halving in 54.3% and NSAIDs stopped entirely in 66.7% — open, retrospective and with no untreated comparator, so it carries the full placebo effect.

The class also turns out to be immunogenic when injected: antibodies to the extract, chiefly IgG4, appeared in 7 of 17 patients after a single injection series and in all four patients who had received nine series or more, alongside rises in IL-5 and IL-10. That is the injected route, and nothing follows automatically for a capsule — but it is a measurement, where the concern used to be theoretical.

Where the evidence comes from

Twenty-seven records make up the appraised literature for Sigumir and Cartalax together. Two carry no author from the St Petersburg institute: a 2025 review of the tetrapeptide AEDG by pharmacy and geriatrics groups in Warsaw and Bydgoszcz, and a study of short peptides in tobacco roots from the All-Russia Research Institute of Agricultural Biotechnology. Neither concerns cartilage. The human joint work comes from a second Russian cluster — Iordanishvili and colleagues at the Kirov Military Medical Academy and Mechnikov North-Western State Medical University — which carries no institute affiliation but publishes in the institute-linked journal Advances in Gerontology and co-authors with the institute's director elsewhere. The Rumalon trials are the exception: Czech, Czech-American and German groups, published in Osteoarthritis and Cartilage and the Journal of Rheumatology, on a different product in the same class.

Regulatory status and safety

Sigumir is sold as a supplement, typically "20 mg complex" capsules taken one to two daily in 30-day courses. No indexed publication validates that dose, and it has no FDA approval or evaluation for any indication. A clinicaltrials.gov search in August 2026 found no registered trial; the phase-2 osteoarthritis trial in Russia asserted in the institute's 2023 review has no locatable registry entry or publication.

No safety data have been published for the capsule beyond the absence of reported adverse events in the 62-patient series. For an oral animal-tissue extract the open questions are source-animal control and batch composition, neither of which has been published, and whether short peptides survive digestion — modelled once computationally against the gut peptide transporters, never measured. This entry is research appraisal, not dosing guidance.

What would move this off anecdotal

The cheapest change is a sentence: any publication stating that the cartilage polypeptide complex in the 2023 chondrocyte work is the preparation in the capsule would let this entry stand on that laboratory record rather than beside it. Beyond that, the useful studies are a replication of the chondrocyte and chondrogenesis results by a laboratory with no institute author, an independent analysis of what several batches of the capsules contain, and registration of the Russian osteoarthritis trial so its result becomes checkable either way.